AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01511081 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBPT (stereotactic body proton therapy)
Description: 50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
Study NCT02321345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Support
Description: Palliative care meetings Quality of Life Assessments
Study NCT03743701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: The method of transrectal ultrasound in В-mode
Description: A linear transrectal ultrasonic sensor with a frequency of 9 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. In real time, the rectal wall and anatomical structures of the anal canal are evaluated using linear sections. The localization of the internal fistula opening, the course of the fistula relative to the fibers of the external sphincter and the presence or absence of cellular and wall plug is determined.
Study NCT03743701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The method of transrectal ultrasound examination using three-dimensional image reconstruction.
Description: A mechanical circular transrectal ultrasonic sensor with a frequency of 13 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. Within 30 seconds with a scan interval of 2 mm with a length of 10 cm, a circular recording of the anatomical structures of the rectum, surrounding tissue and anal canal takes place, obtaining an array of images in the form of a cube. The study was completed. After, at a convenient time for the researcher is working with a three-dimensional array of images. The resulting cube can be rotated 360 degrees in a circle of its axis, work with the sagittal, frontal and axial plane. To obtain a more visual representation of the exact localization of the internal fistula orifice, the course of the fistula relative to the fibers of the outer sphincter and to design volumetric cellular and wall plug.
Study NCT03600532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teachable Moment Brief Intervention (TMBI)
Description: Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt.
Study NCT04138290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predictix Antidepressant Software tool
Description: Predictix Antidepressant is a stand-alone software tool based on a patients' genetic panel, clinical, demographic and behavioral inputs, intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with Major Depressive Disorder.
Study NCT03073993 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: feeding tube insertion
Description: Feeding tube was inserted in hemodynamically stable babies for purpose of feeding
Study NCT02982941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: enoblituzumab administered IV weekly for up to 96 weeks
Study NCT01850407 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Education Counseling
Study NCT02072369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VAEDA Glove
Description: Voice And EMG-Driven Actuated glove used during training
Study NCT02072369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: novel upper extremity occupational therapy focused on the hand
Study NCT02072369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: novel upper extremity occupational therapy focused on the hand
Study NCT03817268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy
Description: Capecitabine is administered within 6 weeks after resection and after adequate recovery. To reduce the side effects and improve patient compliance, the administered dose is half of the recommendation: 625 mg/m2, bis in die (BID) (1250 mg/m2 per day). A 2-week therapy is followed by a 1-week pause, and a cycle includes 3 weeks. A total of 8 cycles is planned for each patient.
Study NCT02464722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1 mcg/kg iv loading dose of remifentanil over a period of 60 seconds. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min.
Study NCT02464722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.
Study NCT02464722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
Study NCT02464722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
Study NCT02464722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthesia was induced with propofol 2 mg kg-1
Study NCT01025427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir, tenofovir/emtricitabine
Description: 16 controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
Study NCT02464722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia was induced with propofol 2 mg kg-1
Study NCT02464722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Anesthesia was induced with rocuronium 0.6 mg kg-1
Study NCT02464722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Anesthesia was induced with rocuronium 0.6 mg kg-1
Study NCT05268952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid biopsies
Description: Blood/urine sampling and scans are done at regular intervals
Study NCT05268952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)
Description: Scans will be done at regular intervals
Study NCT00206713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: 6 μg/kg sargramostim administered SC once daily for 8 weeks
Study NCT00206713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered SC once daily during the randomized retreatment phase.
Study NCT03382808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEE Training
Description: Participants are first presented with a fixation cross which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a neutral and a fearful image (face) of the same model identity. The fearful expression is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with neutral and 75% fearful expressions only in the first session; the intensity of the fearful cue is successively decreased by 15% at every subsequent session.
Study NCT03382808 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GAZE Training
Description: Participants are first presented with a fixation cross, which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a direct gaze-image (neutral face) and an image of a neutral face (same model identity) displaying deviated gaze. The averted gaze-face is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with direct and 100% averted gaze images only in the first session; the intensity of the deviated gaze cue is successively decreased by 20% at every subsequent session.
Study NCT02808468 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Cognitive Therapy
Description: Cognitive strategies to help achieve balanced thinking around sexual assault and alcohol use
Study NCT01226576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgFUS Treatment
Description: Local treatment of prostate cancer using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy
Study NCT04465292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab Prefilled Syringe
Description: Patients will receive Tildrakizumab 100 mg subcutaneously at Weeks 0, 4, and 16. The study staff will administer each dose.
Study NCT03139344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-frequency Exercise
Description: The quadriceps/hamstrings will perform exercise via the application of low-frequency electrical stimulation.
Study NCT03139344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency Exercise
Description: The quadriceps/hamstrings will perform exercise via the application of high-frequency electrical stimulation.
Study NCT00167310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (omega-3 fatty acid)
Description: 2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
Study NCT00167310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
Study NCT03188510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC
Study NCT04254094 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological scales
Description: Basic Activity of Daily Living (BADL) and Instrumental Activities of Daily Living (IADL), Neuropsychiatric Inventory (NPI), Cornell Scale for Depression in Dementia (CSDD), Clinical Dementia Rating Scale (CDR) and defining dementia criteria. Also as part of this study, an MRI examination at baseline and at 18 months follow-up will be performed in the Bordeaux center
Study NCT01325805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Weight Loss Program
Description: Those patients randomized to the structured weight loss group will have a formal evaluation and counseling a medical endocrinologist specializing in weight management. The structured weight loss program will consist of meeting with a dietician who will guide them on following a hypocaloric diet with a calorie deficit of 750kcal/day. The weight loss goal will be to lose 1-1.5 pounds/week. The participants will receive teaching utilizing the American Diabetes Association Exchange Lists and will receive sample meal plans. In addition, participants will be seen by the dietitian once a week for a month, then every 2 weeks for 2 months, then once per month for 3 months. Patients randomized to the study group will continue in the structured weight loss program for 6 months.
Study NCT01325805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Weight Loss Counseling
Description: Participants randomized to the routine weight loss counseling group will receive the ACOG Patient Education pamphlets on obesity.
Study NCT02083497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rigid bandage
Study NCT02083497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elastic bands
Study NCT02083497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: without the use of banding
Study NCT04954157 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Phase-1: Breath Holding Test
Description: In this phase of the study, each subject will be asked to hold their breath for up to 60 seconds or until they can longer hold it. While they are holding their breath, subjects will be hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
Study NCT04954157 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Phase-1: Breath Holding Test
Description: In this phase of the study, each subject will be asked to hold their breath for up to 60 seconds or until they can longer hold it. While they are holding their breath, subjects will be hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
Study NCT04954157 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2: 6-Minute Walk Test (6MWT)
Description: In this phase of the study, each subject will be asked to walk for 6 minutes in their hospital room or hallway. Their rate of perceived exertion will be measured while also hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
Study NCT04954157 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Phase 2: 6-Minute Walk Test (6MWT)
Description: In this phase of the study, each subject will be asked to walk for 6 minutes in their hospital room or hallway. Their rate of perceived exertion will be measured while also hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
Study NCT01805557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-DHAP
Description: * Rituximab 375 mg/sqm iv day 0 or 1~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy
Study NCT01805557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-DHAP
Description: * Rituximab 375 mg/sqm iv day 0 or 1~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy
Study NCT01805557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-DHAP
Description: * Rituximab 375 mg/sqm iv day 0 or 1~* Bortezomib SC 1.5 mg/sqm day 1, day 4~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days.
Study NCT03540199 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer
Description: CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
Study NCT03540199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT03540199 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT03052049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostate Artery Embolization
Description: The PAE procedure will be completed on all enrolled patients in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Bead Block microspheres to slow/block blood flow to the prostate.
Study NCT00186901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (Tums), vitamin D
Description: Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day
Study NCT00186901 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02380040 — intervention group
Intervention type: DEVICE
Intervention: PPG
Description: A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software
Study NCT00122369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnotic Relaxation
Description: A research assistant read to the patient a self-hypnotic relaxation script while displaying empathic attention.
Study NCT00122369 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empathic Attention
Description: A research assistant displayed defined behaviors of empathic attention.
Study NCT00122369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic Attention
Description: A research assistant displayed defined behaviors of empathic attention.
Study NCT04000204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYAJOINT Plus
Description: 60 mg / 3 ml cross-linked hyaluronan, SciVision Biotech Inc.
Study NCT00990314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium Modified Release
Study NCT03114631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with tumor lysate
Study NCT03114631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with MUC-1/WT-1 peptides
Study NCT03617146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: The intervention will seek to help participants express their diabetes emotional needs and to work with them to figure out what can be done to meet those needs. Depending on the unique needs of each participant, the coaching approach for this study will include: improving motivation and self-efficacy for diabetes management using motivational interviewing and appreciative inquiry; building trust and rapport through mindful listening, open-ended inquiry, and perceptive reflections; and expressing empathy through nonviolent communication. Each participant will receive eight individual coaching sessions over a five month period. All coaching sessions will be delivered over the phone (i.e. telecoaching). The coaching intervention will be done by a certified health and wellness coach.
Study NCT03617146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Distress-specific Education
Description: A diabetes distress-specific education that explains what diabetes distress is, why it matters, and its four domains. In addition, the participant is given feedback on his or her distress score and advised on ways to deal with the areas of greatest distress. Participant is linked with resources to overcome any expressed needs. The education is provided by a trained medical assistant.
Study NCT03617146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Distress-specific Education
Description: A diabetes distress-specific education that explains what diabetes distress is, why it matters, and its four domains. In addition, the participant is given feedback on his or her distress score and advised on ways to deal with the areas of greatest distress. Participant is linked with resources to overcome any expressed needs. The education is provided by a trained medical assistant.
Study NCT01088399 — intervention group
Intervention type: DRUG
Intervention: Somatropin (rDNA origin)
Description: Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
Study NCT02825199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: capsule: 300mg caffeine
Study NCT02825199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non caffeine
Description: capsule: placebo (maize starch)
Study NCT01549925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Surgical resection
Description: standard surgical resection using clamps and surgical ligatures
Study NCT01549925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LIGASURE
Description: resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
Study NCT00400569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate (SU011248)
Description: For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.
Study NCT02459678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Adherence Package
Description: The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.
Study NCT01355692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd: YLF laser treatment
Description: grid selective retinal treatment
Study NCT04520321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114(NM141)
Description: engineered FGF-1 delivered intracamerally